^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JANX008

    i
    Other names: JANX008, EGFR-TRACTr, JANX 008, JANX-008
    Associations

    News

    Trials
    Company:
    Janux Therapeutics
    Drug class:
    EGFR inhibitor, T-cell stimulant, CD3 modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=130, Recruiting, Janux Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    JANX008
    over1year
    Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=130, Not yet recruiting, Janux Therapeutics
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    JANX008
    2years
    Preclinical Activity and Safety Profile or JANX008, a Novel EGFR-Targeting Tumor-Activated T Cell Engager for Treatment of Solid Tumors (SITC 2022)
    Finally, the cleavable albumin-binding domain extended the half-life of JANX008 to ~94h, relative to the ~1.3h half-life of non-masked TCE, supporting its weekly clinical dosing. Conclusions Preclinical data demonstrate key characteristics of JANX008, including cleavage-dependent activity, half-life extended PK, the potential for superior safety, and manufacturability properties that could mitigate significant limitations of TCEs and support JANX008 clinical development.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • EGFR expression
    |
    JANX008